Patent ID: 8753633
Filing Date: 2014-06-17
Classification: A61K,A61P,C07K,Y02A,Y10S

Abstract:
1. A method of treating a human subject having an inflammatory bowel disease, said method comprising administering an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, to the subject, wherein the antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising a complementarity determining region 3 (CDR3) domain comprising the amino acid sequence as set forth in SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 7, a heavy chain variable region (HCVR) comprising a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 8, and an IgG1 or an IgG4 heavy chain constant region.